IE912199A1 - Antiparasitic agents - Google Patents

Antiparasitic agents

Info

Publication number
IE912199A1
IE912199A1 IE219991A IE219991A IE912199A1 IE 912199 A1 IE912199 A1 IE 912199A1 IE 219991 A IE219991 A IE 219991A IE 219991 A IE219991 A IE 219991A IE 912199 A1 IE912199 A1 IE 912199A1
Authority
IE
Ireland
Prior art keywords
phenyl
alkoxy
halo
optionally substituted
compound according
Prior art date
Application number
IE219991A
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of IE912199A1 publication Critical patent/IE912199A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Antiparasitic compounds of formula (IV) wherein R is H, -OH, -OR<3>, -OCOR<4> or -OCONHR<4>, R<1> R<2> R<3> and R<4> may be variety of organic substituents and X is O or a direct link, or wherein R is -OH, R<1> is O, R<2> is H and X is O, are made by fermentation of Penicillium paraherquei CM1 68220 followed if necessary by synthetic steps.

Description

This invention relates to new antiparasitic agents and in particular to a family of novel compounds related to paraherquamide and to a process for their preparation, to compositions containing them, and to their use in veterinary or human medicine.
Paraherquamide is a compound produced under certain conditions by the fungal organism Penicillium paraherguei.
Details of the structural and spectroscopic characteristics of paraherquamide are described in Yamazaki et. al. Tetrahedron Letters. 22. 135-136 (1981). Subsequently it has been discovered that paraherquamide together with same related ccmpounds are produced by the fungal organism Penicillium charlesii and furthermore these compounds possess potent activity against a range of endo- and ecto-parasites as described in EP-A-0301742 and EP-A-0322937.
We have now discovered a family of novel ccmpounds produced by fermentation under controlled conditions of the organism Penicillium paraherguei vhich is a known microorganism deposited at the C.A.B. International Mycological Institute, Ferry Lane, Kew, London, under the deposit number CMI 68220. These novel compounds possess potent activity against a broad range of endoand ecto-parasites afflicting animals, man and plants.
PLC 541 Thus in one aspect the present invention provides compounds of the formulai- and their non-toxic salts, in which (i) X is 0 and R is CH, (ii) X is 0 and R is H, or (iii) X is a direct link and R is H.
The compounds (i), (ii) and (iii) are identified, respectively, by the Pfizer references UK-110123, UK-109692, and UK-105166.
In a further aspect the present invention provides a conpound of the formula (II) identified by the Pfizer reference UK-112847. and its non-toxic salts.
PIC 541 ΙΕ 912-Γ99Γ The compounds (I) are distinguished frcm previously known paraherquamides in that they lack a methyl substituent at N-30, extending the numbering system described in Blizzard et. al., Journal of Organic Chemistry. 54. 2657-2663 (1989). Ihe stereochemistry of the compounds (I) and (II) has not been determined absolutely but is inferred by comparison with the related cortpounds described in the literature. However this invention relates to those compounds produced by the fermentation as subsequently described and as defined by their specific spectroscopic and chromatographic properties and is not intended to be limited to compounds having the particular stereochemical structures shown in formulae (IA) and (IIA) belcw although these are believed to be correct:- PLC 541 It is disclosed in EP-A-0301742 and EP-A-354615 that certain synthetic derivatives of the natural product paraherquamide also possess antiparasitic activity. For example, the compound obtained from paraherquamide by catalytic hydrogenation under the conditions described by Yamazaki et. al.. Tetrahedron Letters. 22, 135-136 (1981), i.e. 24,25-dihydroparaherquamide, is an active antiparasitic agent. We have also found that the analogous 24,25-dihydro derivatives correspondingly obtained from the compounds of formula (I) have antiparasitic activities. Thus in a further aspect the invention provides compounds of the formula (III):u Me Mi CH H (III) and their non-toxic salts wherein (i) X is 0 and R is OH or (ii) (iii) X is O and R is H X is a direct link and R is H PIC 541 In a yet further aspect of this invention we have found that the hydrogen atom attached to N-30 in the compounds of the formulae (I) and (III) can te replaced by certain alkyl, alkanoyl or arylsulphonyl substituents to obtain antiparasitic derivatives of paraherquamide not previously known. This can be achieved by treating a solution of a compound of the formula (I) or (III) with a strong base such as lithium diisqpropylamide, n-butyl lithium, sodium hydride, potassium hydride, potassium hydroxide or potassium tert-butoxide in a suitable organic solvent such as tetrahydrofuran, toluene, dimethylsulphoxide, dimethylformamide or ether, followed by the addition of an appropriate alkylating or acylating or sulphonating reagent. Depending on the precise conditions used and the choice of alkylating or acylating reagent additional reaction may also take place at position N-l. If this is not desired, this position may be protected conventionally, for example by prior reaction with diazcmethane to give the 2-O-methylimidate using conditions described in the EP-A-0354615. At the end of the reaction sequence, the protecting group can be removed conventionally, e.g. by treatment with a mineral acid such as hydrochloric acid in an organic solvent such as tetrahydrofuran. In the case of compound UK-110123, an additional competing reaction may occur at the 14-hydroxy group. If this is not desired, the hydroxy group can be protected conventionally, for example by silylation using trimethylchlorosilane or trimethylsilyl triflate in the presence of a base such as triethylamine or with bis (trimethylsilyl) acetamide in a suitable solvent. Such a protecting group can subsequently be removed PLC 541 conventionally at the end of the reaction sequence by treatment with a dilute mineral acid (including hydrofluoric acid) in a water-miscible solvent such as tetrahydrofuran, or by treatment with a solution of tetrabutyl ammonium fluoride in tetrahydrofuran, lhe alkylating agent used may be an alkyl iodide, alkyl bromide or an alkyl sulphonate. The acylating agent may be an acyl chloride, acyl bromide, acyl anhydride, a chloroformate ester or an isocyanate. The sulphonating agent used can be an optionally substituted benzenesulphonyl chloride or anhydride. Thus in this aspect, the invention provides compounds of the general formula (IV), which also possess significant antiparasitic and anthelmintic activity, of the formula:(IV) CH and their non-toxic salts; PL£ 541 where R is H, -OH, -OR3, -OCOR4 or -OCONHR4; 3.,.
R is (l) Cn-Co alkyl optionally substituted by halo, X o hydroxy, C^-C^ alkoxy or phenyl, (ii) alkenylalkyl having 3 to 8 carbon atoms in total, (iii) alkynylalkyl having 3 to 8 carbon atcms in total, or (iv) benzyl; .
R is C^-Οθ alkyl optionally substituted by halo, C^-C^ alkoxy or phenyl; R1 is (i) H, (ii) C “C alkyl optionally substituted by halo, hydroxy, C^-C^ alkoxy or phenyl, (iii) alkenylalkyl having 3_to8 cartoon atoms in total, (iv) alkynylalkyl having 3 to 8 carbon atoms in total, (v) . 5 5 benzyl (vi) a group of the formula -COR or -OONHR where R is either (a) C^-Οθ alkyl optionally substituted by halo, Cj-C4 alkoxy or phenyl, or (b) phenyl or (vii) -S02·phenyl ; R2 is (i) alkyl optionally substituted by halo, hydroxy, Cj-C4 alkoxy or phenyl (ii) c2~Cq alkenyl (iii) C_-Co alkynyl, (iv) benzyl, (v) a group of the formula —CDR5 6 or -OONHR6 where R6 is either (a) ^-Οθ alkyl optionally substituted by halo, C^-C4 alkoxy or phenyl or (b) phenyl, or (vi) -SO2.phenyl; X is O or a direct link with the provisos that (a) when R is other than Η, X is 0 and also (b) when R is H or 1 2 .
OH, at least one of R and R is other than H; and the dotted line represents an optional bond; said phenyl groups, and the phenyl portion of said PLC 541 benzyl groups, all being optionally substituted by up to three substituents each independently selected from C^-C4 alkyl, C^-C4 alkoxy, hydroxy and halo.
When appropriate, the alkyl, alkoxy, alkenyl and alkynyl groups can be straight or branched chain. Halo means F, Cl, Br or I.
In the compounds (III), the preferred alkyl, alkoxy, alkenyl and alkynyl groups have up to 4 carbon atoms. lhe non-toxic salts of the compounds of the above-mentioned compounds include pharmaceutically-acceptable acid addition salts such as the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, besylate, citrate, fumarate, gluconate, lactate, maleate, mesylate, pamoate, succinate and tartrate salts. For a more comprehensive list of pharmaceutically acceptable salts see, for example, the Journal of pharmaceutical Sciences, Vo. 66, No. 1, January 1977, pages 1-19. These salts can be prepared conventionally, e.g. by mixing a solution of the free base and the acid in a suitable solvent, e.g. ethanol, and recovering the acid addition salt either as a precipitate, or by evaporation of the solution.
PLC 541 Ihe compounds (III) and (IV) are also believed to have the following stereochemistry:- The compounds of the formula (I) can be prepared by the aerobic fermentation of Penicillium paraherquei CMI 68220 in stirred aqueous or static solid nutrient media. Such conditions are similar to those conventionally employed to produce antibiotics by fermentation.
Cultivation may take place in an aqueous nutrient medium containing suitable sources of carbon, nitrogen and trace elements PLC 541 for a period of several days under aerobic conditions, typically at a temperature in the range from.24° to 36°C. As with the majority of antibiotic fermentations, the amount of the compound produced will vary with changing fermentation conditions especially with regard to nutrient components, aeration conditions and pH. Ihe progress of the fermentation can be monitored by an appropriate analytical technique such as high pressure liquid chromatography (hplc) coupled with a suitable detector such as a U.V. spectrophotometer. Significant amounts of the desired compounds are generally found ip both the mycelial and aqueous phases of the whole broth although the proportion in each phase will depend on the fermentation conditions. Isolation of the products is facilitated by the greater solubility of the compounds UK-110123, UK-109692, UK-105166 and UK-112847 in a range of organic solvents than in water provided that the pH is adjusted to be greater than 4. Thus in one recovery procedure the whole fermentation broth is extracted, preferably with a water-immiscible solvent such as methylene chloride, chloroform, hexane, petroleum spirit, ethyl acetate, butanol or methyl isobutyl ketone. Maximum recovery is achieved by repeating the extraction several times. Ihe solvent extract is concentrated to dryness and the crude product is further purified as necessary by chromatography.
In an alternative recovery procedure the whole fermentation broth may be filtered and the mycelium and filtrate extracted separately. In this case the mycelium may be extracted by a range PIC 541 of water-miscible solvents such as methanol, ethanol, acetone and the like in addition to those water-immiscible solvents listed above. After filtration the solvent extract is concentrated and either freeze-dried or further extracted with a water-immiscible solvent to give a crude material suitable for further purification by chromatography. lhe filtrate derived from the whole broth may be recovered in an exactly similar manner to the whole broth as described above or, alternatively, it may be passed through a column containing a suitable polystyrene resin such as Diaion HP20 (Trade Mark - available frcm Mitsubishi Chemical Company) which retains the desired products but allows many impurities to pass through. After washing the column with water, the column is eluted with an organic solvent such as ethanol, methanol or acetone, lhe solvent is then evaporated to give a crude mixture containing the compounds, lhe crude mixture containing the compounds UK-110123, UK-109692, UK-105166 and UK-112847 as obtained by any of the above procedures is further enriched using column chromatography, thin layer chromatography or similar technique using for example silica gel as the chromatographic medium and eluting with a suitable solvent or combination of solvents as is known to those skilled in the art. Final purification of the individual compounds may be achieved by repeated column chromatography, hplc or preparative thin layer chromatography.
PLC 541 Alternatively, the cultivation of Penicillium paraherguei CMI 68220 may take place on a static nutrient medium under aerobic conditions at a temperature typically in the range of from 24° to 36°C for several days. The medium together with the mycelial growth is then extracted with an organic solvent such as methanol or ethyl acetate, filtered and concentrated to give a crude product vhich is further purified by the techniques described above.
Thus the present invention also provides a process for producing the ccmpounds UK-110123, UK-109692, UK-105166 and UK-112847 as previously defined, vhich comprises cultivating the microorganism Penicillium paraherguei CMI 68220, or a mutant, genetically transformed or recombinant form thereof having the ability to produce the compounds UK-110123, UK-109692, UK-105166 and UK-112847 in stirred aqueous or static solid culture media containing an assimilable source of carbon, nitrogen and inorganic salts, under aerobic fermentation conditions until a recoverable amount of said compound is obtained.
The term mutant includes any mutant strain vhich arises spontaneously or by the application of known techniques, such as exposure to ionising radiation, ultraviolet light, and/or chemical mutagens such as N-methyl-N-nitroso-urethane, nitrosoguanidine and ethane methane sulphate, etc. Genetically transformed and recombinant forms include mutants and genetic variants produced by genetic engineering techniques, including for example recombination, transformation, transduction, and protoplast fusion, etc.
PLC 541 As previously mentioned the compounds of the formulae (I), (II), (III) and (IV) are highly active antiparasitic agents having particular utility as anthelmintics, ectoparasiticides, insecticides and acaricides.
Thus the compounds (I), (II), (III) and (IV) are useful in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most frequently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting domestic animals and poultry, lhe compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria in dogs and various parasites vhich can infect humans including gastro-intestinal parasites such as Ancylostoma. Necator. Ascaris, Strongyloides, Trichinella. Capillaria. Trichuris. Enterobius and parasites vhich are found in the blood or other tissues and organs such as filiarial worms and the extra intestinal stages of Strongyloides and Trichinella. lhe compounds are also of value in treating ectoparasite infections including in particular arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae vhich can affect cattle and horses.
PLC 541 The ccmpounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphids, caterpillars and against migratory orthopterans such as locusts.
Ihe compounds may be administered as a formulation appropriate to the specific use envisaged and to the particular species of host and animal being treated and the parasite or insect involved. For use as an anthelmintic the compounds may be administered orally in the form of a capsule, bolus, tablet or liquid drench, or alternatively, they may be administered as a pour-on or by injection, either subcutaneously or intramuscularly. Capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier, additionally containing a disintegrating agent and/or binder such as starch, lactose, talc, or magnesium stearate. A drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents and injectable formulations may be prepared in the form of a sterile solution or emulsion.
Pour-on and injection formulations are prepared in a conventional manner in accordance with standard veterinary practice. These formulations will vary with regard to the weight of active compound depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host. Generally for oral administration a dose of from about PLC 541 to 100 mg per kg of animal body weight given as a single dose or in divided doses for a period of frcm 1 to 5 days will be satisfactory but of course there can be instances where higher or lcwer dosage ranges are indicated and such are within the scope of this invention.
As an alternative the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
For use as insecticides and for treating agricultural pests the compounds can be applied as, sprays, dusts, pour-on formulations, emulsions and the like in accordance with standard agricultural practice.
For human use the canpounds are administered as a pharmaceutically-acceptable formulation in accordance with standard medical practice.
The invention is illustrated by the following Example which describes the preparation, isolation and identification of the compounds UK-110123, UK-109692, UK-105166 and UK-112847:'•Ardamine was supplied by Champlain of Clifton, New Jersey, U.S.A. Bacto-Casitone was supplied by the Difco Corporation of Detroit, Michigan.
Ultraviolet spectra were recorded using a Hewlett Packard HP1090A diode array spectrophotometer.
Mass spectroscopy was performed using a VG Trio 3 mass spectrometer. Samples were introduced using a thermospray interface in a matrix consisting of water, methanol and ammonium acetate.
PLC 541 Nuclear magnetic resonance spectral data were obtained using a General Electric GN500 spectrometer, a Nicolet GE 300 spectrometer or a Bruker AC300 spectrometer.
PLC 541 EXAMPLE The culture Penicillium paraherguei CMI 68220, supplied by the C.A.B. International Mycological Institute, Ferry Lane, Kew, London, England, was maintained on agar slants prepared from a medium comprising glucose (10 g), starch (20 g), Bacto-Casitone (Trade Mark) (5 g), yeast extract (5 g), calcium carbonate (1 g) and agar (20 g) made up to 1 litre with tap water and adjusted to pH 7.3 before autoclaving. An inoculum was prepared by washing a slant culture with 10 ml of sterile water into a 3 litre Fembach Erlenmeyer flask containing a medium comprising glycerol (50 g), peptonised milk (5 g), lactic casein (10 g) and Ardamine (1 g) (Trade Mark) made up to 1 litre with tap water and adjusted to ph 7.0. The inoculum was incubated at 28°C on a rotary shaker with a 2.5 cm threw at 170 r.p.m. for 144 hours. The total contents were then transferred to a 100 litre mechanically agitated vessel containing 70 litres of the same medium and incubated at 28 °C until the first signs of pellet formation. This second stage seed culture (10 litres) was used to inoculate a 2000 litre mechanically agitated fermenter containing 1200 litres of the same medium. The fermentation was maintained at 28°C with aeration at 1200 litres per minute and agitation at 250 r.p.m. and the addition of dilute sulphuric acid if necessary at such a rate to prevent the ph rising above 6.4. After 6 days the broth was filtered using a plate and frame press and the mycelium was discarded. The filtrate (1600 litres) was pxmped into ethyl acetate (800 litres) and briefly stirred. After PLC 541 settling the aqueous layer was discarded and the organic extract was washed with saturated brine (60 litres) before evaporating to dryness. The residue (125 g) was suspended in ethyl acetate (125 ml) and filtered. The filtrate was added slowly to petroleum ether (b.p. 40-60°C, 2 litres) with stirring and the precipitate was recovered by filtration. The solid precipitate was then chromatographed on a column of silica gel (600 g, Merck Kieselgel 60 [Trade Mark], 230-400 mesh) eluting with dichloromethane containing an increasing proportion of ethyl acetate. Fractions rich in the compounds UK-110123, UK-109692 and UK-105166 co-eluted when the solvent composition was approximately 1:1 and UK-112847 eluted when the solvent was changed to chloroform-methanol 4:1 and were recognised by silica thin layer chromatography as U.V.-absorbing spots with RFS as tabulated below and giving a characteristic red-purple colouration on spraying with vanillin and sulphuric acid in ethanol and heating. Fractions containing the desired compounds were combined and evaporated to dryness.
Ihe individual compounds were separated by preparative h.p.l.c. using a C-18 bonded phase column and eluting with water-methanol mixtures as known to those skilled in the art. Ihe composition of the fractions collected was monitored by analytical h.p.l.c. using a Beckman Ultrasphere-ODS (Trade Mark) (5/jm) h.p.l.c. column (4.6 x 250 mm) eluting with a water-methanol linear gradient from 1:1 to 100% methanol over 30 minutes at a flow rate of 0.85 ml per minute and monitoring by ultraviolet absorbance at 230 nm. Using these conditions the individual components eluted at the following times:IE 912199 PLC 541 UK-112847 UK-110123 UK-109692 UK-105166 at 11.7 minutes at 14.3 minutes, at 20.6 minutes, and at 21.6 minutes.
Thin layer chromatography (Merck (T.M.) Kieselgel 60) Compound «F CHCl3-MeOi UK-110123 0.25 20:1 UK-109692 0.27 20:1 UK-105166 0.27 20:1 UK-112847 0.55 4:1 The novel components were distinguished and characterised by their spectroscopic properties as follows:IE 912Ϊ99 PLC 541 20 PLC 541 o rH If) o ni JSJS'OO'O’O'O'O-oSe'Slo’OB'OS'cnw ω to In η 5_ 3 3^3^3 3.3.3.3.2.3.3.3.S S 2-C.C.C· oconifM^fOOcioociooinincococooir'inin «cocoScioicM«-ioi'a,cicMr-ir'incocot^^,^,n)o» coc.ioioio^f^i'i'cicicicicitMCMi-ii-irHi-ii-ii-io in in 0 v r- σι N N (N co M* (N •s ’οΙ&'Ο'Ο’ϋ'ο'βΤϊ'Ο’ϋ'ϋ'ίο'ίβ'ίΒ SS333333333333 noot^oicp’fMinoinoMOi coi'-'j-nOiiiHOinNcoi^or' • •••••••«a···· lOlilOOinnnnNNHHrHO W-OO-OO-O 6 L Ό Ό Ό Μ M 33333333333 X X Cl ci (N^H>NC?^NinOinON θΓ»Όί»βιη^ιοιηηι»Γ'θ ···.········· C'lOlOlO^-ClClClCMCarHrHr-l (0 Cl Oi Γ* • ^-o^’O'O'O'O^^Lln'a'-OO'In'ffl'Inln'In s' s' 3' 3 3' 3' 3' 3' 3' 3' 3' 3' 3' s' s' s' S S oo^oicMi-'Cieotnoinoiciocoo p-j^ioionico«n^oioincjoiinxf co cm ci 0 co C'lOOlOlO^ClClClCMCMCM·—IrHrHi—IrHO PLC 541

Claims (12)

1. A ccmpound of formula (IV) or a non-toxic salt thereof: (a) wherein R is H, -OH, -OR 3 , -000R 4 or -OCONHR 4 ; R is (i) C^-Cg alkyl optionally substituted by halo, hydroxy, Cj-C 4 alkoxy or phenyl, (ii) alkenylalkyl having 3 to 8 carbon atoms in total, (iii) alkynylalkyl having 3 to 8 carbon atoms in total, or (iv) benzyl; R 4 is C^-Cg alkyl optionally substituted by halo, C^-C 4 alkoxy or phenyl; R 1 is (i) H, (ii) C„-C_ alkyl optionally substituted by halo, hydroxy, <^-0 4 alkoxy or phenyl, (iii) alkenylalkyl having 3 to 8 carbon atoms in total, (iv) alkynylalkyl having 3 to 8 carbon atcms in total, (v) 5 5 benzyl (vi) a group of the formula -COR or -CONHR 5 where R is either (a) C, -C alkyl optionally i o substituted by halo, C^-C 4 alkoxy or phenyl, or (b) phenyl or (vii) -S0 2 ·phenyl; PLC 541 2. . . R id (l) c i“Cg alkyl optionally substituted by halo, hydroxy, C,-C. alkoxy or phenyl (ii) C„-C_ alkenyl (iii) C_—C alkynyl, (iv) benzyl, (v) a group of the formula Λ o zt ζς z? -COR or -CONHR where R is either (a) C,-C o alkyl optionally substituted by halo, C^-C^ alkoxy or phenyl or (b) phenyl, or (vi) -SC> 2 .phenyl; X is 0 or a direct link with the proviso that when R is other than Η, X is 0; and the dotted line represents an optional bond; or 1 2 . (b) vherein R is -OH, R is 0, R is Η, X is 0 and the dotted line represents a bond, said phenyl groups, and the phenyl portion of said benzyl groups, all being optionally substituted by up to three substituents each independently selected from alkyl, alkoxy, hydroxy and halo. 1 2
2. A compound according to claim 1, vherein R and R are H, the dotted line represents a bond and either (i) X is 0 and R is OH, or (ii) X is 0 and R is H, or (iii) X is a direct link and R is H.
3. A canpound according to claim 1, in which said alkyl, alkoxy, alkenyl and/or alkynyl groups have up to 4 carbon atcms.
4. A compound preparable by fermentation of Penicillium paraherquei CM1 68220 and having one of the following spectroscopic characteristics(i) to (iv):23 PLC 541 H •H •H o cH in JSJS'O'd'O'OO'd'd'S g'S'W'Og'O'S 4-J 8 8 1/1 8 in o cm io cm CM ocpnjpjTfoonoom co oo co h- co σ cm oonooinincococo (Ti-fmwHr'incooo^ in in in in X X X X co co co co x '— OA r- in in M· CM σ r-( r4 (—1 o CO M* M* s '—'-rd 4-» oo a> Μ· M I s-s in in o vr > σ CM CM CM ID M* P M· 0) ID p sf Q O CO M· § s ·γΗ -P o a) co P M· O •a in o CM ID CM CM •a in o CM ID CM CM 'oJSoo'o'o ε+Ι'σ'ϋΌϋΤωϋΓ s 3 3 s s a a a a a a a a a ηα)θ['*σα>'Μ·<Μΐηοιηο<Μσ co>M , c')iomi-ioincMco>or^ lOCDlDlDinnmmCMCMi-li-lr-IO in Ό Ό Ό Ό Ό ε -Ρ Ό τ3 Ό in tn in 3 3 3' 3 3 3' 3' 3 3“ 3' 3' 3' 3' 3 NvTH^NCO-ifMinOinONffi Or'lOCMCOinr-IOinfMCO>Or' r'lDlDlD'TnncOfMCMi—I H H O IS ό IS 555554-555570705075 3333333333333S3 333 οο , Μ·σ(ΜΓ'ηαοιηοιησσοοοοοοίΜθ Γ'η'ΐοιο<ΜοοιηΓ-ιοιοιηίΜσιη^τηοοο Γ^ΙΟΙΟΙΟΙΟ·Μ·Π(ηΠ<Μ<Μ<Μι—Ιι-Ιι—Ii—1 γ-10 PLC 541
5. An antiparasitic compound or composition, substantially as hereinbefore described with reference to the Examples.
6. An antiparasitic composition, comprising a compound according to any one of the preceding claims.
7. An antiparasitic composition, comprising a compound according to any one of claims 1 to 5 and a pharmaceutically acceptable excipient or carrier.
8. A compound according to any one of claims 1 to 5 for use in human or veterinary medicine.
9. Use of a compound according to any one of claims 1 to 5 for making a medicament for treatment or prevention of parasitic infestations.
10. A process for making a compound according to claim 2, 4 or 5, which comprises fermenting in a medium containing assimilable sources of carbon, nitrogen and trace elements micro-organism CM1 68220 or a mutant or recombinant form thereof having the ability to produce said compound, and isolating said compound from the medium.
11. A process according to claim 10, in vhich said fermentation is carried out under aerobic conditions in a stirred aqueous or static solid nutrient medium.
12. A method of preventing or treating parasitic infestations, corprising application of a compound according to any one of claims 1 to 5.
IE219991A 1990-06-26 1991-06-25 Antiparasitic agents IE912199A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909014194A GB9014194D0 (en) 1990-06-26 1990-06-26 Antiparasitic agents

Publications (1)

Publication Number Publication Date
IE912199A1 true IE912199A1 (en) 1992-01-01

Family

ID=10678216

Family Applications (1)

Application Number Title Priority Date Filing Date
IE219991A IE912199A1 (en) 1990-06-26 1991-06-25 Antiparasitic agents

Country Status (4)

Country Link
GB (1) GB9014194D0 (en)
IE (1) IE912199A1 (en)
PT (1) PT98074A (en)
WO (1) WO1992000300A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5394123A (en) * 1991-03-13 1995-02-28 Murata Manufacturing Co., Ltd. Ladder type filter comprised of stacked tuning fork type resonators
US5776936A (en) * 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
TW410227B (en) * 1993-06-16 2000-11-01 Upjohn Co 14-substituted marcfortines and derivatives useful as antiparasitic agents
MY113806A (en) * 1995-07-21 2002-05-31 Upjohn Co Antiparasitic marcfortines and paraherquamides
ZA976761B (en) * 1996-09-09 1999-01-29 Upjohn Co 25 Methylene and 24,25-epoxy marcfortines and paraherquamides
WO1998021211A1 (en) * 1996-11-15 1998-05-22 Pharmacia & Upjohn Company 1- and 2-substituted marcfortines and paraherquamides as antiparasitic agents
MX2012006921A (en) 2009-12-17 2012-07-10 Merial Ltd Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873247A (en) * 1987-11-27 1989-10-10 Goegelman Robert T Derivatives of paraherquamide isolated from a fermentation broth active as antiparasitic agents
US4978656A (en) * 1988-08-12 1990-12-18 Merck & Co., Inc. Synthetic derivatives of paraherquamide

Also Published As

Publication number Publication date
WO1992000300A1 (en) 1992-01-09
GB9014194D0 (en) 1990-08-15
PT98074A (en) 1992-03-31

Similar Documents

Publication Publication Date Title
EP0739344B1 (en) Antiparasitic pyrrolobenzoxazine compounds
EP0170006B1 (en) Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents
PL153429B1 (en) Method of obtaining novel derivatives of avermectine
GB2166436A (en) Antibiotic compounds and their preparation
US5510372A (en) Antiparasitic macrolide antiobiotics
EP0410615B1 (en) Antiparasitic agent
DE68912007T2 (en) Antiparasitic derivatives.
IE912199A1 (en) Antiparasitic agents
US5677332A (en) Antiparasitic agents
IE61513B1 (en) Antiparasitic agents
US4869901A (en) Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents
US5439934A (en) Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents
EP0308145A2 (en) Mylbemycin derivatives with antiparasitic activity
EP0335541B1 (en) Antiparasitic avermectin derivatives
JPH08510758A (en) Method for producing doramectin and anthelmintic intermediate
US5198464A (en) Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents
GB2247016A (en) Antiparasitic agents
EP0674649B1 (en) Antiparasitic agents
JPH07505280A (en) Avermectin compounds glycosylated by Streptomyces avermitilis strains
US4510134A (en) Controlling nematodes in animals and soil with nematocidal antibiotics
DE4225284A1 (en) Clonostachydiol and helmidiol derivs. - for treating flat worms and round worms in mammals and obtd. by fermentation of Clonostachys cylindrospora or Alternaria sp.
PH26844A (en) Antibiotic compounds